
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is expected to continue its positive growth trajectory driven by investments in new products and a focus on diversity and sustainability, offsetting potential risks such as biosimilar competition and patent expirations. The recent divestment of the consumer business and planned separation of a lower-growth division in 2027 also show the company's commitment to driving value for stakeholders.
Bears say
Johnson & Johnson is facing challenges in their drug division due to loss of exclusivity for certain drugs and potential slow uptake of new pipeline products. In their MedTech division, increased competition and M&A integration disruptions could limit growth potential. Furthermore, litigation and settlement costs could negatively impact profits. Despite strong sustainability initiatives and potential growth in the vision segment, the overall uncertainty surrounding the company's financials leads to a negative outlook on their stock.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares